Larkspur Health Acquisition Corp.
LSPRU
NASDAQ Global Market20.80
USD
+10.61
- -
Larkspur Health Acquisition Corp.
LSPRU
(NASDAQ Global Market)
Recent
price
20.80
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Larkspur Health Acquisition Corp. Larkspur Health Acquisition Corp. (LSPRU) operates as a blank check special purpose acquisition company with no significant independent operations; it focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses, targeting the biotechnology sector in the United States. The company offers no core products or services beyond its SPAC structure, which provides public market access via units comprising one share of common stock and three-fourths of one redeemable warrant exercisable at $11.50 per share. Incorporated in 2021 and headquartered at 100 Somerset Corporate Blvd., 2nd Floor, Bridgewater, New Jersey, it conducts no geographic operations outside its U.S.-focused investment mandate. In December 2022, Larkspur Health Acquisition Corp. completed a reverse merger transaction with ZyVersa Therapeutics, Inc., a clinical-stage biopharmaceutical company developing therapies for renal and inflammatory diseases including VAR 200 and IC 100; post-merger, ZyVersa assumed public trading status under the ticker ZVSA on Nasdaq, with Larkspur's structure effectively absorbed and LSPRU units reflecting legacy trading activity as of late 2025. The business combination included up to approximately $77.67 million in trust cash before redemptions—99% of which occurred—and $10 million in committed PIPE financing anchored by institutional investors to support ZyVersa's clinical advancements.